10 recruiting, 8 completed, 5 terminated, 4 active not recruiting. 20 Phase 2, 7 Phase 1, 6 Phase 3, 2 Phase 4.
Follow Pembrolizumab injection: new trials by email Literature Review of Pembrolizumab injection trials Research Report on Pembrolizumab injection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Treatment Delivery Preference In People With Kidney Cancer Nivolumab Injectable Product, Nivolumab, Pembrolizumab injection - Renal Cell Carcinoma, Kidney Cancer | Phase 4 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2026-09-24 | 2026-10-16 |
| A Study of Trastuzumab Rezetecan in Combination With Adebrelimab Versus Investigator's Choice of Therapy in Subjects With Residual Triple Negative Breast Cancer Trastuzumab Rezetecan for Injection, Adebrelimab Injection, Capecitabine tablets - Triple Negative Breast Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 1000 | 2026-09-02 | 2026-09-09 |
| Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer HA131, Enlonstobart Injection, Pembrolizumab Injection - Advanced Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 116 | 2025-12-23 | 2025-12-15 |
| SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma SYS6010 injection, Enlonstobart injection, Pembrolizumab injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 110 | 2025-12-12 | 2026-10-19 |
| A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants BAT3306, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 1 | Active not recruiting | Bio-Thera Solutions | 160 | 2025-10-14 | 2026-09-02 |
| Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC JSKN016, Carboplatin, Furmonertinib Mesylate - Advanced Non-small Cell Lung Cancer | Phase 1 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 288 | 2025-04-02 | 2026-03-30 |
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery Pembrolizumab injection, Capecitabine tablets, Local radiotherapy - Triple Negative Breast Neoplasms | Phase 2 | Recruiting | UNICANCER | 220 | 2025-03-11 | 2025-11-17 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 Ivonescimab Injection, Pembrolizumab Injection - Non-Small Cell Lung Cancer | Phase 3 | Recruiting | Summit Therapeutics | 780 | 2025-02-27 | 2026-09-18 |
| A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC BAT3306, EU-Keytruda®, US-Keytruda® - Carcinoma, Non-Small-Cell Lung | Phase 3 | Terminated | Bio-Thera Solutions | 162 | 2024-07-19 | 2025-12-02 |
| Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab Pembrolizumab injection - Early Breast Cancer, Triple Negative Breast Cancer | Phase 2 | Not yet recruiting | Fundacao Champalimaud | 20 | 2024-07-01 | 2024-04-17 |
| Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK Pembrolizumab injection - ALK Gene Mutation, Lung Adenocarcinoma | Phase 2 | Recruiting | Hunan Province Tumor Hospital | 78 | 2024-05-29 | 2024-05-30 |
| Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) Pembrolizumab injection - Renal Cell Carcinoma | Phase 2 | Recruiting | University of Alabama at Birmingham | 100 | 2024-01-01 | 2025-10-21 |
| Compare the Pharmacokinetics and Safety of BAT3306 Injection Versus KEYTRUDA® Administered in Healthy Male Subjects Recombinant Humanized Anti-PD-1 Monoclonal Antibody Solution for Injection, Pembrolizumab injection - Healthy Male Subjects | Phase 1 | Completed | Bio-Thera Solutions | 59 | 2023-11-05 | 2024-10-30 |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients Ivonescimab Injection, Pembrolizumab Injection - Non-Small Cell Lung Cancer | Phase 3 | Active not recruiting | Summit Therapeutics | 1600 | 2023-10-26 | 2026-10-08 |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer CJRB-101, Pembrolizumab injection - NSCLC, HNSCC | Phase 1 / Phase 2 | Recruiting | CJ Bioscience, Inc. | 160 | 2023-09-11 | 2024-12-20 |
| A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors NM1F Injection, Pembrolizumab injection - Ovarian Cancer, Melanoma | Phase 1 | Recruiting | Hefei TG ImmunoPharma Co., Ltd. | 38 | 2023-04-13 | 2024-01-26 |
| Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors ICT01, Proleukin Injectable Product, Pembrolizumab injection - Solid Tumor, Adult | Phase 1 / Phase 2 | Terminated | ImCheck Therapeutics, an Ipsen company | 56 | 2022-05-04 | 2026-07-30 |
| A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) TQB2450 injection, Anlotinib Hydrochloride Capsules, Pembrolizumab injection - Non Small Cell Lung Cancer | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 375 | 2021-08-06 | 2021-08-20 |
| Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab UV1, Sargramostim for Injection, Pembrolizumab injection - Head and Neck Squamous Cell Carcinoma | Phase 2 | Unknown | Martin-Luther-Universität Halle-Wittenberg | 75 | 2021-08-02 | 2022-03-09 |
| Neoadjuvant Study of PD-1 Inhibitor Pembrolizumab in PD-1 Naive Cutaneous Squamous Cell Carcinoma (cSCC) Pembrolizumab Injection - Squamous Cell Carcinoma | Phase 2 | Active not recruiting | Diwakar Davar | 30 | 2021-05-11 | 2026-10-20 |
Showing 20 of 32. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (7) · Triple Negative Breast Neoplasms (4) · Squamous Cell Carcinoma of Head and Neck (3) · Carcinoma, Renal Cell (2) · Colorectal Neoplasms (2) · Head and Neck Neoplasms (2) · Melanoma (2) · Adenocarcinoma Of Esophagus (1) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Carcinoma in Situ (1) · Carcinoma, Squamous Cell (1) · Esophageal Squamous Cell Carcinoma (1) · Inflammatory Breast Neoplasms (1) · Kidney Neoplasms (1)
Bio-Thera Solutions (3) · Summit Therapeutics (2) · AHS Cancer Control Alberta (1) · AIO-Studien-gGmbH (1) · Beijing Friendship Hospital (1) · CG Oncology, Inc. (1) · CJ Bioscience, Inc. (1) · CSPC Megalith Biopharmaceutical Co.,Ltd. (1) · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Diwakar Davar (1) · Fundacao Champalimaud (1) · Hefei TG ImmunoPharma Co., Ltd. (1) · Hunan Province Tumor Hospital (1) · ImCheck Therapeutics, an Ipsen company (1)
China (12) · United States (12) · France (5) · Germany (5) · South Korea (4) · Canada (3) · United Kingdom (3) · Belgium (2) · Greece (2) · Italy (2) · Japan (2) · Mexico (2) · Poland (2) · Portugal (2) · Serbia (2)
Xiaorong Dong, Dr. (2) · Anthony Goncalves, Pr (1) · Charles A Peyton, MD (1) · Daniel Catenacci, MD (1) · Diwaker Davar, MD, M.Sc (1) · Fatima Cardoso, MD (1) · Hecheng Li, MD&PHD (1) · Indu Lal (1) · Jose Monzon, MD (1) · Katrien Lemmens, MD, PhD (1) · Li Zhang (1) · Mascha Binder, MD (1) · Ruey-Long Hong, MD PhD (1)
PMID 33330051, PMID 33373868, PMID 35046059, PMID 36003437, PMID 37647728, PMID 38384801, PMID 38844794, PMID 39267574, PMID 40220758, PMID 40764401, PMID 41309527, PMID 41825453, PMID 41935492, PMID 42140743, PMID 42346219
2016 (1), 2019 (1), 2023 (1)